MedTrace Logo

Post Marketing Surveillance (PMS) Study for Velaglucerase Alfa (VPRIV) in India

NCT04429984 · Status: COMPLETED · Type: OBSERVATIONAL · Enrollment: 21

Last updated 2023-06-07

No results posted yet for this study

Summary

The main aim of this study is to measure the safety and to find out the effects of VPRIV in participants with Gaucher disease using both retrospective and prospective data when used in the post-marketing setting and to collect genetic mutation data from participants with Gaucher disease.

This study is about collecting data available in the participant's medical record as well as data from each participant's ongoing treatment. No study medicines will be provided to participants in this study.

When the participants start the study, they will visit the study clinic close to approximately 12 months.

Conditions

  • Gaucher Disease

Sponsors & Collaborators

  • Shire

    lead INDUSTRY

Principal Investigators

  • Study Director · Shire

Eligibility

Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2021-07-28
Primary Completion
2023-04-22
Completion
2023-04-22

Countries

  • India

Study Locations

More Related Trials

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT04429984 on ClinicalTrials.gov